Abstract
This research quantifies the various South African lockdown regimes, for the SARS-CoV-2 pandemic, in terms of the basic reproduction number, r0. It further calculates the levels of immunity required for these selfsame lockdown regimes to begin to work, then predicts their perceived values, should infections have been underestimated by a factor of 10. The first, level-5 lockdown was a valiant attempt to contain the highly infectious, SARS-CoV-2 virus, based on a limited knowledge. Its basic reproduction number (r0 = 1.93) never came anywhere close to the requirement of being less than unity. Obviously, it could be anticipated that the same would apply for subsequent, lower levels of lockdown. The basic reproduction number for the level-3 lockdown was found to be 2.34 and that of the level-4 lockdown, 1.69. The suggestion is therefore that the level-4 lockdown might have been marginally ‘smarter’ than the ‘harder’, level-5 lockdown, although its basic reproduction number may merely reflect an adjustment by the public to the new normal, or the ever-present error associated with data sets, in general. The pandemic’s basic reproduction number was calculated to be 3.16, in the Swedish context. The lockdowns therefore served to ensure that the medical system was not overwhelmed, bought it valuable time to prepare and provided useful data. The lockdowns nonetheless failed significantly in meeting any objective to curtail the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data publically available, online, and listed in the bibliography.